Lipocine Inc.
LPCN
$3.56
$0.257.55%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 492.81% | 358.33% | 8,629.09% | 748.90% | -670.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 492.81% | 358.33% | 8,629.09% | 748.90% | -670.16% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 492.81% | 358.33% | 8,629.09% | 748.90% | -670.16% |
| SG&A Expenses | 1.97% | 12.92% | 19.09% | 26.48% | 20.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.08% | -10.89% | 5.06% | 8.64% | 19.50% |
| Operating Income | 93.56% | 70.42% | 29.43% | 22.18% | -47.95% |
| Income Before Tax | 100.06% | 75.12% | 29.61% | 19.50% | -51.99% |
| Income Tax Expenses | -12.50% | 85.71% | 85.71% | 14.29% | 14.29% |
| Earnings from Continuing Operations | 100.05% | 75.12% | 29.60% | 19.50% | -51.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 100.05% | 75.12% | 29.60% | 19.50% | -51.99% |
| EBIT | 93.56% | 70.42% | 29.43% | 22.18% | -47.95% |
| EBITDA | 93.78% | 70.57% | 29.57% | 22.36% | -47.83% |
| EPS Basic | 100.16% | 75.57% | 30.57% | 19.98% | -50.62% |
| Normalized Basic EPS | 100.17% | 75.58% | 30.58% | 21.75% | -47.20% |
| EPS Diluted | 98.70% | 75.02% | 32.51% | 25.72% | -40.65% |
| Normalized Diluted EPS | 99.37% | 75.41% | 30.32% | 21.35% | -47.51% |
| Average Basic Shares Outstanding | 1.32% | 1.56% | 1.57% | 1.05% | 0.86% |
| Average Diluted Shares Outstanding | 3.10% | 1.76% | 1.69% | 1.04% | 0.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |